(Q46736547)
Statements
1 reference
A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study (English)
1 reference
Eastern Cooperative Oncology Group
1 reference
B A Burtness
1 reference
J Manola
1 reference
R Axelrod
1 reference
A Argiris
1 reference
A A Forastiere
1 reference
21 February 2008
1 reference
1 reference
19
1 reference
5
1 reference
977-983
1 reference
Identifiers
1 reference
1 reference